Brief: Exscientia Begins Human Trials For Bristol Myers In-Licensed PKC Theta Inhibitor EXS4318
02/02/2023 14:31
Feb 2 (Reuters) - Exscientia PLC EXAI.O :
* EXSCIENTIA ANNOUNCES FIRST-IN-HUMAN STUDY FOR BRISTOL
MYERS
SQUIBB IN-LICENSED PKC THETA INHIBITOR, EXS4318
* EXSCIENTIA LTD - EXS4318 IS ELIGIBLE FOR PRE-COMMERCIAL
MILESTONE PAYMENTS AND, IF APPROVED, TIERED ROYALTIES ON NET
PRODUCT SALES
* EXSCIENTIA - BRISTOL MYERS SQUIBB WILL OVERSEE CLINICAL &
COMMERCIAL DEVELOPMENT
Source text for Eikon: ID:nBw4m43jTa
Further company coverage: EXAI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Exscientia
See all newsExscientia PLC expected to post a loss of 9 cents a share - Earnings Preview
Brief: Exscientia Achieves Milestones For Two Programmes In Sanofi Collaboration
Exscientia PLC reports results for the quarter ended in June - Earnings Summary
Deals of the day-Mergers and acquisitions
Biotech firm Recursion to buy smaller peer Exscientia for $688 million